MiMedx Group

Vericel Corporation

Dilution score: 20/100 (LOW), 24.0 months cash

Short interest: 6.18% of float, squeeze risk: MODERATE

In Vitro, Ex Vivo and Clinical Trial of Brightening Serum Using a Novel Delivery System on Subjects With Moderate to Severe Dyschromia.

Deucravacitinib, an oral, selective, allosteric, tyrosine kinase 2 inhibitor, in patients with active SLE: efficacy on patient-reported outcomes in a phase II randomised trial.

Long-term safety and efficacy of anti-GM-CSF otilimab in patients with rheumatoid arthritis: long-term extension of three phase 3 randomised trials (contRAst X).

Immunogenicity of adalimumab reference product and adalimumab-adbm in patients with rheumatoid arthritis, Crohn's disease and chronic plaque psoriasis: a pooled analysis of the VOLTAIRE trials.

Upadacitinib monotherapy versus methotrexate monotherapy in patients with rheumatoid arthritis: efficacy and safety through 5 years in the SELECT-EARLY randomized controlled trial.

Dilution score: 12/100 (LOW), 999.0 months cash

Short interest: 7.1% of float, squeeze risk: MODERATE

Short interest: 7.13% of float, squeeze risk: MODERATE

Short interest: 7.11% of float, squeeze risk: MODERATE

SW convergence: 50/100 (Neutral), 0 bullish / 0 bearish signals

Short interest: 6.31% of float, squeeze risk: MODERATE

SW convergence: 50/100 (Neutral), 1 bullish / 1 bearish signals

Short interest: 6.33% of float, squeeze risk: MODERATE

<article class="bts-verified-summary" data-ticker="MDXG">
<p>MiMedx Group (MDXG) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov<sup><a href="#fn-1">[1]</a></sup>.</p>
<p>MDXG has 5 Form 4 insider filings recorded at the SEC in the past 30 days<sup><a href="#fn-2">[2]</a></sup>.</p>
<section class="sources" data-nosnippet aria-label="Sources"><h3>Sources</h3><ol><li id="fn-1">ClinicalTrials.gov (2026-04-11) <a href="https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22MiMedx+Group%22&amp;aggFilters=status%3Arec%2Cact" rel="nofollow noopener noreferrer">↗</a></li>
<li id="fn-2">SEC EDGAR · 0001376339 (2026-04-11) <a href="https://efts.sec.gov/LATEST/search-index?q=%22MDXG%22&amp;forms=4&amp;dateRange=custom&amp;startdt=2026-03-12&amp;enddt=2026-04-11" rel="nofollow noopener noreferrer">↗</a></li></ol></section>
</article>

ClinicalTrials.gov

SEC EDGAR — 0001376339

MiMedx Group (MDXG) — BioTechSigns Verified Summary

MiMedx Group (MDXG) is the lead sponsor of 2 active clinical trials listed on ClinicalTrials.gov[1].

MDXG has 5 Form 4 insider filings recorded at the SEC in the past 30 days[2].

Sources:
[1] ClinicalTrials.gov. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://clinicaltrials.gov/search?term=AREA%5BLeadSponsorName%5D+%22MiMedx+Group%22&aggFilters=status%3Arec%2Cact
[2] SEC EDGAR, 0001376339. Source last updated 2026-04-11, retrieved 2026-04-11.
    https://efts.sec.gov/LATEST/search-index?q=%22MDXG%22&forms=4&dateRange=custom&startdt=2026-03-12&enddt=2026-04-11

The purpose of this survey is to observe the efficacy and safety of EPIFIX® dehydrated human amnion/chorion membrane (DHACM) for the treatment of intractable diabetic foot ulcers or venous leg ulcers.

Post-Marketing Surveillance of Dehydrated Human Amnion/Chorion Membrane (DHACM) in Non-Ischemic Chronic Wounds

This study will evaluate two human amnion/chorion membrane (ppLHACM) products and Standard of Care (SOC) versus SOC alone in the closure of nonhealing diabetic foot ulcers (DFUs).